Résumé

DARC
The history of human knowledge on DARC (Duffy Antigen Receptor for Chemokines) begins in 1950 with the discovery of a new blood groups system (the Duffy blood group system) named from the person who developed the first antibody against the so called Fya antigen [1] . A second antithetic antigen Fyb [2] was shortly after discovered. In 1955, it was shown that antigens of Duffy blood group system were missing in red blood cells (named Fy(a-b-)) from a large proportion of West African ascent population (RBC-WAAP) [3] . It was observed thereafter that these cells were resistant to invasion by Plasmodium vivax (see below). Other important steps were cloning of cDNA coding for the protein carrying the Fy antigens, the Duffy glycoprotein, the recognition that Duffy glycoprotein was a transmembrane receptor for chemokines leading to changing its name to DARC.
In this short review, we will briefly overview knowledge on the immunogenic properties of DARC, relations of DARC with malaria, of DARC with chemokines inflammation and inflammatory diseases. We will quote present research which deals with the multiple roles of this somewhat enigmatic protein that, besides malaria and inflammation, is implicated in cancer and might play a role in HIV infection and AIDS. Then, we show the interests in the design of structural models for DARC analysis. We will present (i) how to build proper structural models of DARC [4] , (ii) how to elucidate pertinent interactions with its ligands [5] and (iii) what might be the role of structural modelling in elaboration of new tools for DARC studies [6] .
Duffy antigens.
They have been defined by studying reactivity of patients immunized through transfusion or pregnancy. Fya/Fyb allotypic variants exist and correspond to a SNP in exon 2 encoding a Gly42Asp substitution in the extracellular N-terminal domain of the Duffy glycoprotein [7, 8] ). Two other antigens have been identified: (i) Fy3, which involves residues from the 3rd extracellular loop [9] , is probably a conformational reader and (ii) Fy6, which was discovered after immunisation of mice with human red cells or engineered eukaryotic cells expressing DARC, is a linear epitope contained in the first extracellular domain. Fy6 is present both in Fya or Fyb allotype, and, only Fy(a-b-) cells do not react with anti Fy6.
The mechanism of selective extinction of expression of Duffy related antigens on WAAP red cells have been elucidated. The Duffy negative phenotype of WAAP red cells (noted Fy(a-b-)) is due to homozygosity for a promoter polymorphism (-46C) in which the binding site for the transcription factor (GATA-1), required for DARC to be expressed on the cell surface of erythrocytes [10] , is disrupted. This mutation is present in a Fyb genetic background. Importantly in Fy(a-b-) WAAP, DARC is normally expressed on cells in which DARC expression was already demonstrated for example, endothelial cells of post capillary veinules, epithelial cells of collecting ducts of the kidney, cerebellar Purkinje cells [11, 12] . Another promoter is likely operative in these tissues.
DARC and Plasmodium vivax. DARC was characterized as an erythrocyte receptor for malaria parasite through in vitro studies and also in vivo experiments performed on American volunteering detainees [13, 14] . The hypothesis that DARC might be a receptor for P. vivax raised after it was noted that WAAP might be resistant to infection by P. vivax purportedly performed to treat neuro syphilis. All this does support the widely accepted hypothesis that P. vivax was the driving force for fixing the mutation silencing red cell expression of DARC. In this regards, it is interesting to note that in Papua New Guinea, where P. vivax malaria is also endemic, heterozygous individuals for the same GATA-1 site mutation have been found [15] but on a Fya background. It is tempting to speculate that the same FY GATA-1 mutation in Africans and Melanesians occurred independently in these two populations as a result of the same selection pressure.
Plasmodium vivax Duffy binding protein (PvDBP) is a merozoite microneme ligand vital for blood-stage infection, which makes it an important candidate vaccine for antibody-mediated immunity against vivax malaria [16, 17] . Naturally acquired antibodies to DBP seem to confer protection from blood-stage P. vivax infection, supporting the development of a vaccine against P. vivax malaria [18] . However other studies also pinpointed that produced human antibodies might have low efficiencies underlining the difficulty of vaccine design [19] . Hence, alternative approaches to interfere with P. vivax merozoite with DARC on red cells are demanded.
Consequently, analysis of interaction mechanisms between DARC and DBP is important; analysis of DBP variants and DARC genotypes gives also insights to the sequence -function relationship [20] .
Very recently, studies have shown that in Madagascar, P. vivax can invade Fy(ab-) erythrocytes leading to disease [21] . Further studies are necessary to identify the genetic peculiarities of the parasite strain the receptors that enable this DARCindependent P. vivax invasion of human erythrocytes.
Beyond DARC and PvDBP it is worth to notice the existence of Duffy-Binding like (DBL) domains implicated in other types of malaria. Domains related to PvDBP are found in Plasmodium falciparum. DBL domains are conserved regions of erythrocyte membrane protein 1 (PfEMP1) family. VAR2CSA Duffy binding-like (DBL) domains, which bind chondroitin sulphate A in placenta, are interesting candidates for the development of a vaccine against pregnancy-associated malaria [22] . Indeed, in spite of the extreme polymorphism of PfEMP1 DBL domains, specific antibodies reducing risk of malaria in areas with high transmission rates were acquired [23] . DBLs family fold is supposed to be conserved. Consequently, the family is intensively studied to elucidate binding mechanisms [24] [25] [26] [27] .
DARC and chemokines. DARC is a transmembrane receptor for a variety of chemokines of both CXC and CC classes, including angiogenic (ELR + ) CXC chemokines, but not angiostatic (ELR -) CXC chemokines [28, 29] . DARC sequence is quite different from other chemokines receptors [30, 31] . It is a silent chemokine receptors (or interceptors) [29] . Besides, a clear distinction should be made between DARC expressed on red cells and DARC expressed in other tissues. Importantly, DARC is lacking the DRY consensus sequence that is necessary to activate a protein G dependant activation cascade after activation by ligand binding [8, [32] [33] [34] . DARC on red cells does not internalize. DARC might play the role of a buffer or a scavenger for chemokines and could reduce their concentration in blood stream [35] . By contrast DARC on endothelial cells behaves differently. It supports transcytosis of chemokines from luminal to extravascular space and favours leucocyte migration and development of inflammatory reactions [36] . A similar mechanism might operate in in vitro model of rheumatoid arthritis in which overexpression of DARC does favour inflammatory reaction [37] . DARC could play a role in inflammatory diseases of the kidney [38] .
Heterodimerization of DARC with CCR5 might impair activation of intracellular signalling dependant on chemokine binding to CCR5 [39] . This observation definitely adds a level of complexity and makes the role of DARC difficult to understand. [41, 43] , but this proposition is also still highly debated [44] [45] [46] .
DARC and cancer.
Recently, a relation between DARC and various cancers was established, making DARC a hot topic. Hence, it seems that DARC and murine CXC Chemokine Receptor-2 Receptors have opposite role in murine melanoma tumor growth [47, 48] . Epidemiological studies showed that African Americans are suffering from prostate cancer earlier than Caucasians. Moreover, the course of the disease appears more aggressive for African American population. These observations suggested that DARC might play a role in cancer. These observations were backed up by crossing DARC null engineered mice with TRAMP mice which developed spontaneous prostate cancer [28] . The scavenger role of DARC for chemokines to excess in red cells could participate in reducing angiogenesis, and consequently the progression of prostate cancer, by clearing angiogenic chemokines from the tumour microenvironment [28, 49] . Hypothesis has been discussed on the substantially higher levels of prostate cancer and associated mortality rates in men of African origin compared with Caucasian men. On the other hand, expression of DARC in breast cancer tumour cells does lower metastasis and aggressiveness of the tumour [50] .
Again, interaction of DARC with chemokines is hypothesized to explain a putative role of DARC in cancer progression noticeably angiogenic chemokines that are obviously implicated in tumour neovascularisation.
The different aspects of the research
All these data clearly suggests that DARC is a particularly interesting and important protein. Various DARC mutants have been designed and expressed.
Affinities with DARC natural ligand, CXCL8, and different antibodies [33, [51] [52] [53] [54] [55] [56] [57] [58] confirmed predictions made about DARC topology [59] . This transmembrane protein as bona fide GPCR has 7 transmembrane segments with four extracellular loops (named Extra Cellular Domains or ECDs) and four intracellular loops (named Intra Cellular Domains or ICDs). The first ECD (ECD1) is a long Nterminal segment, while last ICD (ICD4) is a short cytosolic Cterminal.
Structural information can help a lot to understand its function and implications in diseases [60] . However, few transmembrane protein structures (~ 650 structures, 1% of the Protein Databank [61] [62] [63] ) are nowadays available [64, 65] . Due to the membrane environment [66] [67] [68] [69] that stabilises the 3D fold, it is particularly difficult to extract, to purify to crystallise and finally to solve transmembrane proteins structures by X-ray crystallography. Hence, structural modeling is an obligatory but difficult step. With a low number of available 3D structures, automatic homology modeling cannot be applied to GPCR or GPCR-like molecules even though it was attempted: at best position of transmembrane membrane domains may be predicted but no solid information on structure of loops may be gained. Thus, pertinent structural models of transmembrane proteins must be a human supervised process using classical approaches coupled with various secondary structure predictions, refinement of sequence alignment, and if possible considering helix -helix and helix -lipid interactions. Importantly, experimental data are necessary for building relevant models [70] .
In the next section, we will detail a concrete application and explain how experimental data were crucial for building pertinent structural models [4] . These models were particularly helpful to explain DARC interaction with its ligands. We will present the principle of docking methods applied to this kind of protein and the specific difficulties met when dealing with DARC [5] . Finally, we will discuss the interest of proposing structural models of camelids VHHs shown to bind a specific DARC epitope [6] .
Building structural models
Classically, a structural model can be elaborated through different strategies from homology/comparative modelling, threading ab initio or de novo approaches, depending on the sequence identity and the availability of structural homologous. Figure I shows a rough description of the sequence identity needed for each of these approaches. If the sequence identity is high, homology modelling could be used. In the twilight zone, when PSIBLAST is unable to detect any interesting sequences, threading approach could help to find distant homology by evaluating sequencetemplate structure fold compatibility. [71, 72] . It has to be noticed that all these approaches were developed for globular proteins.
For the building of DARC of structural models, we started with comparative modelling. The procedure first consists in searching for homologous sequences in PDB. However, classical tools did not provide any convincing answer. The sequence identity between DARC and rhodopsin (PDB code: 1F88 [73] ), the paradigm for 7-TM fold, was very low, i.e., only 12% in the range of random alignment).
Consequently, sequence alignment was not meaningful and no clear homology could be inferred. Moreover, DARC family members were too few to detect important conserved residues from divergent ones with the sole alignment. Consequently, the absence of real sequence divergence makes the alignment not truly informative.
Actually, pertinent structural models could not be properly built with the sole sequence information of DARC. However, for DARC, important biological data were available. Indeed, more than 40 different punctual DARC mutants were experimentally tested for affinity with natural ligands or some antibodies [9, 53, 74] , they underline the potential accessibility of some residues. With this information, it was possible to guide the building of structural models. Figure II presents [95] , MEMSAT [96, 97] , PRODIV-TMHMM [98] and MemBrain [99] ). All these methods claim to be efficient with significant prediction rates when tested on benchmark datasets. Only the first helix is predicted with a large consensus. The fourth helix was particularly difficult to delimit. Other helices could also diverge by an impressive number of residues, i.e., 15 residues. The most recent prediction tools, e.g., MINNOU [100] were not necessarily the most efficient ones. Indeed, in some cases, PSI-PRED [101] mainly trained on globular protein, could give better results than dedicated approach, as seen in [102] .
In a second step, using a rough consensus definition of transmembrane regions, predicted helices were aligned with assigned transmembrane helical (DSSP software [103] )segments of rhodopsin (PDB code 1F88 [73] ). Strong efforts were dedicated to the prediction of ECD1 and ICD4 [104, 105] . Hundred models were generated using
Modeller software [106] [107] [108] . Each model was then refined: (i) the side chains were repositioned using one of the most efficient approach, i.e., SCWRL [109] . We performed simulated annealing for exploring connection loops conformations using GROMACS software [110, 111] . The residue accessibility was computed with Naccess software [112] and the results were compared to experimental data available.
We focused on residues involved in antibody binding that are supposed to be accessible. The alignment was then modified accordingly. Twelve generations of alternative alignments were tested for finally obtaining two structural models that diverge by the topology of ECD1. (see Figure III [113] ). In these two models, the accessibility values of important residues were large enough to allow binding.
Since, novel approaches have been developed and adapted to transmembrane proteins. We revisited our models at the light of the most efficient new tools and compared with our results. For this purpose, we tested LOMETS (LOcal MEtaThreading-Server [114] ), a webserver that uses 8 different methods and ranks the results. Table I summarizes the different results obtained for MUSTER [115] , SAM [116] , PROSPECT2 [117] , SP3 [118] , PPA-I, HHsearch [119] , SPARKS2 [120] , and FUGUE [121] . The three first methods provide structural models with a medium confidence rate while the models constructed with the last methods are associated with a low confidence index. Only half of the proteins used as template are transmembrane proteins, half are globular proteins with often beta-sheets. Figure IV describes the main results obtained from LOMETS [114] and from PHYRE [122] .
Figures IVa, IVd and IVg show the three templates found by LOMETS for the medium scored structural models. The first one is based on the famous human A2A adenosine receptor (PDB code 3EML [123] ), while the two others are globular proteins, namely the COPI gamma-subunit (PDB code 1PDZ [124] ) and cell vibrio mixtus mannosidase 5A (PDB code 1UUQ [125] These revisited models obtained with up-to-date methods show the importance of considering biological data to produce pertinent structural models. It also reinforces the validity of the structural models we constructed some years ago.
Structural properties of DARC
To explore the flexibility of the ECD loops, we performed simulated annealing simulations [127] . Interestingly, the procedure highlights the importance of residue D263 which was never really accessible in any structural models; this residue constrains the local fold by creating a bridge with ECD3. Analysis of simulations with Protein Blocks [104, 128] showed that that some regions in ECD1 tent to be more helical and other ones to be more extended. These results correlated well with the predictions done [105, 129, 130] .
The two extreme positions of ECD1 (see Figure III) could also reflect also the domain motions [60] . We performed normal mode analysis (NMA) using different webservices. This methodology has been recently re-popularized and successfully applied for examining dynamics of large systems and also for transmembrane proteins
[reference]. Among the different webservers, WEBnm@ server [131] provides additional analysis dedicated to transmembrane protein. For this review, we also tested Nomad-Ref [132] and ElNemo [133, 134] . In NMA, the lowest frequencies modes are associated with the largest amplitude of motions. a large domain motion of ECD1 that gets closer to the other ECDs was observed with the different NMA tools.
A similar motion was indeed observed with Nomad-Ref [132] or ElNemo [133, 134] . Electrostatic potentials of DARC model and its natural ligand CXCL8 were calculated using the finite-difference Poisson-Boltzmann (FDPB) method [135] . Two distinct zones can be observed in potential interaction zones with CXCL8. The first one is highly negative and encompass the residues implicated in epitope Fy6. The second one is highly positive. CXCL8 also shows two regions with opposite features (one positive and the remainder negative, encompassing the loop 40s known to interact with chemokine receptor). Our results highlight regions with significant electrostatic properties in agreement with experimental studies that underline the importance of electrostatics in the binding of chemokines [136, 137] .
A following question is the potential use of such structural models for understanding the binding of DARC and its ligands. Docking methods are particularly appropriate to locate binding sites on both partners and their relative orientation, even though the use of models increases the risk of obtaining irrelevant structures of complex. Docking procedure roughly consists in moving the smallest partner (designed as "the ligand") on the surface of the largest molecule ("the receptor"). For each position, a score (or energy) is computed. The position with the optimal score is finally selected. A source of errors comes from the inadequacy of scoring to represent binding energies. In addition, most docking at least in the first steps, consider the partners as rigid. This limitation is only alleviated in a final refining step when a subset of solutions has been already established. In the case of DARC, we previously underlined that ECD1 is highly flexible. Clearly, this property must be accounted.
Consequently, we performed the study in two steps and we designed a docking approach that combines rigid and flexible docking. In a first step, DARC structural model is cut into ECD1 and the rest of the protein (see Figure VIa) to find correct positioning of CXCL8 on DARC without ECD1, and a flexible docking only with ECD1 and CXCL8 (see Figure VI) . On one side, a flexible docking of ECD1 is done with structure of CXCL8 (see Figure VIb) thanks to ICM [138, 139] software. It is very difficult and complex approach with a very high computing consuming time. On the other side, a rigid docking is done with the transmembrane domain of DARC (see Figure VIc) thanks to ClusPro [140, 141] webserver. Each experiment give numerous possibilities, the docking conserved where selected on energetic properties of the complex and also using biological data. Figure VII shows examples of results of rigid docking (see Figure VIIa and VIIb) and of final combination of rigid and flexible docking (see Figure VIIc and VIId). These results were quite encouraging. Finally, both results will be combined to perform a deeper search [60] . Further optimization needs to be done, but conserved results are in accordance with expected residues in contacts.
Modelling of camelid VHHs
DARC is implicated in numerous human diseases. Dedicated tools are demanded for analyzing DARC role and guiding therapeutic strategies. In this field, antibodies and their recombinant derivatives are of great use. The heavy chain-only antibodies found in camelids are composed of heavy chains and lack all light chains [142] . VHHs (or nanobodies), which correspond to the domain in the heavy chainonly antibody, can be derived. In this domain is located the antigen recognition region. VHHs are easily cloned from lymphocytes from naive or immunized camelids; they can be expressed in E. coli with a good yield and have an excellent solubility [143] . Moreover, they have proved to be efficient as therapeutic and diagnostic agents [144, 145] .
A dromedary has been immunized with ECD1 of DARC expressed in E. coli.
As presented earlier, ECD1 carries several sites important to DARC functions and properties (binding to chemokines and PvDBP, Fya/Fyb allotypes, the Fy6 epitope).
A VHH library from dromedary's lymphocytes was built and screened using also E. Sequences related to CA52 were searched with PSI-BLAST software [147] applied on Protein DataBank [61] . Using default parameters of PSI-BLAST, one VHH (PDB code 1XFP [148] ) was selected with a very good sequence identity (75%). However, all the structural models obtained presented a topology inversion between two loops. A careful analysis of PSI-BLAST results showed that CDR3 regions were considered as non-informative (i.e., coiled-coil as detected by SEG [149] ) although this CDR is the most important one for the binding. When SEG was disabled, PSI-BLAST search gave VHHs structural templates better matching for CDR3 (both in length and sequence identity). A first structure (PDB code 1OP9 [146] ) was selected (a sequence identity of 75% and a good alignment with CDR3). 107. This disulfide bond is of major biological importance. We considered a second template to 1OP9, namely 1JT0 [150] that possesses a similar extra-disulfide bridge.
The protein sequences were aligned with Clustalw2 software [151] and some manual changes were done. The model construction was performed with the Modeller software [107] . Final structural models showed few differences as constant regions strongly constrained the topology and the extra-disulfide bridge constraints strongly
CDRs. Topology was assessed using ProCheck software [152] . Figure . A global alignment is done and used to generate structural models. (d) Structural models are optimized and important residues are manually analyzed. The alignment is then manually modified and new structural models are generated. The process is done until most of the concerned residues are accessible.
Conclusions and Perspectives
-23 - structural templates used by LOMETS [114] for its medium quality structural models. (a): human A2A adenosine receptor (PDB code 3EML [123] ), (d) COPI gammasubunit (PDB code 1PDZ [124] ), (g) cell vibrio mixtus mannosidase 5A (PDB code 1UUQ [125] ). (b) and (c) two views of the structural model based on human A2A adenosine receptor (PDB code 3EML [123] ), (e) and (f) two views of the structural model based on COPI gamma-subunit (PDB code 1PDZ [124] ). (h) the structural model based on bovine rhodopsin structure (PDB code 1U19 [126] ) obtained by PHYRE [122] . Tables   Table I. Results of LOMETS webserver.
